重要内容提示： 证券代码：688185 证券简称：康希诺 公告编号：2023-056 康希诺生物股份公司 关于召开 2023 年半年度暨第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 （网址：http://roadshow.sseinfo.com） 说明会议召开方式：上证路演中心网络互动 投资者可于 2023 年 11 月 9 日（星期四）至 11 月 15 日（星期三）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司投资者关系邮箱 （ir@cansinotech.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 康希诺生物股份公司（以下简称"公司"）已于 2023 年 8 月 31 日发布 2023 年半年度报告，并于 2023 年 10 月 31 日发布 2023 年第三季度报告，为便于广大 投资者更全面深入地了解公司经营成果、财务状况，公司计划于 2023 年 11 月 16 日（星期四）上午 11:00-12:00 举行 2023 年半年度暨第 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥149,723,992.40, representing a 92.93% increase compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2023 was -¥143,600,577.66, a decrease of 70.49% year-on-year[4]. - Year-to-date net profit attributable to shareholders reached -¥985,029,654.47, showing a significant increase of 107.63% compared to the same period last year[4]. - The company's operating revenue for the current reporting period increased by 92.93%, primarily due to a significant rise in sales of meningococcal vaccines compared to the same period last year[25]. - Year-to-date operating revenue decreased by 75.17%, mainly due to a substantial decline in sales of COVID-19 vaccines, which had a large contribution in the previous year[25]. - The net profit attributable to shareholders for the current reporting period showed a decrease of 70.49%, reflecting a net loss for the period[25]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, decreased by 64.54% in the current reporting period[25]. - The company reported a net loss of approximately ¥1,454.92 million for the current period, compared to a net loss of ¥488.68 million in the previous period, indicating a significant decline in profitability[35]. - The company’s total profit for the current period was approximately -¥1,456.08 million, compared to -¥646.85 million in the previous period, indicating a significant increase in losses[34]. - The comprehensive income total for the third quarter of 2023 was -CNY 1,454,797,112.46, a significant decline from -CNY 488,625,829.08 in the same quarter of 2022[51]. Research and Development - Research and development expenses totaled ¥140,476,879.33 in Q3 2023, a decrease of 38.80% year-on-year[23]. - Research and development expenses for the current reporting period decreased by 38.80%, as the focus shifted away from COVID-19 vaccine-related R&D[25]. - The ratio of R&D expenses to operating revenue was 93.82%, a decrease of 201.94 percentage points compared to the previous year[23]. - The ratio of R&D expenses to operating revenue decreased by 201.94 percentage points in the current reporting period[25]. - Research and development expenses decreased to approximately ¥461.67 million from ¥549.07 million, showing a reduction in investment in R&D[34]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥9,610,642,425.30, down 19.34% from the end of the previous year[23]. - The equity attributable to shareholders was ¥5,770,626,650.09, a decrease of 16.94% compared to the previous year[23]. - The total liabilities amounted to ¥3,812,394,223.51, down from ¥4,223,356,561.52 in the previous year[18]. - The total assets as of September 30, 2023, amounted to approximately CNY 9.61 billion[31]. - The total liabilities as of September 30, 2023, were approximately CNY 2.47 billion[31]. - Total current assets decreased to CNY 5,527,055,428.52 as of September 30, 2023, from CNY 7,730,184,538.12 at the end of 2022[43]. - Inventory as of September 30, 2023, was CNY 417,379,697.15, a decrease from CNY 677,776,961.91 at the end of 2022[43]. - Non-current assets increased to CNY 2,873,570,857.79 as of September 30, 2023, from CNY 2,891,316,509.78 at the end of 2022[43]. Cash Flow - The net cash flow from operating activities was -¥748,974,021.75, reflecting a 46.24% decline compared to the previous year[23]. - The company recorded a net cash outflow from operating activities of approximately -¥748.97 million, an improvement from -¥1,393.28 million in the previous period[39]. - Cash and cash equivalents at the end of the period totaled approximately ¥2,350.99 million, down from ¥2,964.82 million at the end of the previous period[40]. - The company's cash and cash equivalents as of September 30, 2023, were CNY 3,221,172,324.19, down from CNY 3,464,734,156.87 at the end of 2022[43]. - Cash inflow from operating activities for the first three quarters of 2023 was CNY 615,809,046.71, down from CNY 763,592,237.08 in the same period of 2022[52]. - Cash received from sales of goods and services in the first three quarters of 2023 was CNY 311,333,825.97, compared to CNY 374,158,061.76 in the same period of 2022[52]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 23,196[26]. - The largest shareholder, HKSCC NOMINEES LIMITED, held 39.63% of the shares[26]. - Basic and diluted earnings per share for the third quarter of 2023 were both -CNY 3.99, compared to -CNY 1.92 in the same quarter of 2022[51].

Financial Performance - The company's operating revenue for the third quarter was RMB 149,723,992.40, representing a 92.93% increase compared to the same period last year[4]. - The net profit attributable to shareholders for the third quarter was a loss of RMB 143,600,577.66, a decrease of 70.49% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 186,431,076.05, down 64.54% from the previous year[4]. - The overall operating revenue for the year-to-date period was RMB 175,631,799.90, reflecting a decrease of 75.17% compared to the same period last year due to a significant drop in COVID-19 vaccine sales[4]. - The company experienced a net loss attributable to shareholders of RMB 985,029,654.47 for the year-to-date period, an increase of 107.63% compared to the previous year[4]. - The net loss for the first three quarters of 2023 was ¥1,454,919,925.84, compared to a net loss of ¥488,682,218.46 in the same period of 2022, representing an increase in losses of about 197.5%[24]. Research and Development - Research and development expenses totaled RMB 140,476,879.33 for the quarter, a decrease of 38.80% compared to the same period last year[4]. - Research and development expenses decreased by 38.80% in the current reporting period, mainly due to a shift in focus away from COVID-19 vaccine-related R&D[10]. - The proportion of R&D expenses to operating income decreased by 201.94 percentage points in the current reporting period[10]. - The proportion of R&D expenses to operating income increased by 194.71 percentage points year-to-date, indicating a larger decline in operating income compared to R&D expenses[10]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 9,610,642,425.30, a decrease of 19.34% from the end of the previous year[5]. - The equity attributable to shareholders at the end of the reporting period was RMB 5,770,626,650.09, down 16.94% year-on-year[5]. - As of September 30, 2023, total assets amounted to ¥9,610,642,425.30, a decrease from ¥11,468,958,286.71 as of December 31, 2022, representing a decline of approximately 16.1%[18]. - Total liabilities decreased to ¥3,812,394,223.51 from ¥4,223,356,561.52, reflecting a reduction of about 9.7%[20]. - The total equity attributable to shareholders decreased to ¥5,770,626,650.09 from ¥6,748,089,902.12, a decline of about 14.5%[21]. Earnings Per Share - The basic earnings per share for the third quarter was a loss of RMB 0.58, a decrease of 70.46% compared to the same period last year[4]. - Basic and diluted earnings per share for the first three quarters of 2023 are both (3.99) CNY, up from (1.92) CNY in the same period of 2022, reflecting improved profitability[26]. Cash Flow - The net cash flow from operating activities decreased by 46.24% year-to-date, primarily due to reduced cash payments for raw materials[9]. - Cash flow from operating activities for the first three quarters of 2023 shows a net outflow of (748,974,021.75) CNY, an improvement from a net outflow of (1,393,277,778.30) CNY in the same period of 2022[28]. - Cash inflow from investment activities for the first three quarters of 2023 is 6,640,825,701.63 CNY, down from 9,360,944,181.35 CNY in the same period of 2022[29]. - Cash flow from financing activities for the first three quarters of 2023 shows a net outflow of (131,319,499.65) CNY, compared to a net inflow of 628,604,712.22 CNY in the same period of 2022[29]. - The net increase in cash and cash equivalents for the first three quarters of 2023 is (1,040,273,125.42) CNY, with an ending balance of 2,350,994,729.85 CNY[30]. Sales Performance - The company reported a significant increase in sales revenue from its meningitis vaccine products, contributing to the rise in operating revenue for the quarter[8]. - The revenue from the combined meningococcal vaccine reached approximately 371.15 million RMB in the first three quarters of 2023, a year-on-year increase of approximately 476.47%[14]. - The total sales revenue for the group was approximately 414.39 million RMB, with a revenue reduction of approximately 238.76 million RMB due to returns[14].

证券代码：688185 证券简称：康希诺 公告编号：2023-055 根据协议，盖茨基金会将向公司提供合计超过 200 万美元的项目资助，以支 持公司基于病毒样颗粒（virus-like particle，VLP）的脊髓灰质炎疫苗 VLP-IPV 的开发。盖茨基金会将根据项目研发目标/里程碑的达成情况，按约定的付款时 间表分阶段支付项目资助。 VLP-IPV 基于公司的蛋白结构设计和 VLP 组装技术开发，有望为全球控制 乃至根除脊髓灰质炎作出贡献。VLP-IPV 是一种非传染性脊髓灰质炎疫苗，在生 产过程中不依赖活病毒，预期具有良好的安全性和免疫原性。与已上市的脊髓灰 质炎减毒疫苗和灭活疫苗不同，非传染性的 VLP 脊髓灰质炎疫苗被世界卫生组 织推荐作为未来消灭脊髓灰质炎的首选疫苗之一。 为了使脊髓灰质炎疫苗在发展中或欠发达国家中广泛使用并可负担，公司将 确保及时并广泛地传播从该项目中获取的知识和信息，并以可负担的价格向发展 中国家最需要的人群提供受资助的开发成果。 康希诺生物股份公司 自愿披露关于与比尔及梅琳达·盖茨基金会 签署重组脊髓灰质炎疫苗项目资助协议的公告 本公司董事会及全体董事保证本公告内容不存 ...

（於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 香港，2023年10月17日 於本通告日期，董事會包括執行董事Xuefeng YU博士、Shou Bai CHAO博士、朱 濤博士、Dongxu QIU博士及王靖女士；非執行董事林亮先生、梁頴宇女士及肖治 先生，以及獨立非執行董事韋少琨先生、辛珠女士、桂水發先生及劉建忠先生。 （股份代號：6185） 董事會會議通告 康希諾生物股份公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，董事會 會議將於2023年10月30日（星期一）舉行，藉以（其中包括）考慮及批准本公司及 其附屬公司截至2023年9月30日止九個月的第三季度業績及其發佈。 承董事會命 康希諾生物股份公司 Xuefeng YU 董事長 ...

FF301 本月底法定/註冊股本總額： RMB 247,449,899 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 688185 | 說明 | | A 股 (上海證券交易所科創版) | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 114,778,999 | RMB | | 1 RMB | | 114,778,999 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 114,778,999 | RMB | | 1 RMB | | 114,778,999 | | I. 法定/註冊股本變動 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 ...

证券代码：688185 证券简称：康希诺 康希诺生物股份公司 投资者关系活动记录表 编号：2023-007 □特定对象调研 □分析师会议 投资者关系 □媒体采访 □业绩说明会 活动类别 □新闻发布会 □路演活动 □现场参观 √其他（业绩交流会、股东大会、IR电话等） OrbiMed、Balyasny、Zeal、LAV、IFC、MassAve、Manulife、Panvie 参与单位名 w、Capital、T. Rowe Price、信达澳亚、人保资产、睿远基金、华夏 称及人员姓 久盈、工银瑞信、华商基金、凯石投资、高毅资产、汇添富、博裕资 名 本、国投瑞银、鑫巢资本、中欧基金等约100余名投资者 ...

证券代码：688185 证券简称：康希诺 公告编号：2023-054 康希诺生物股份公司 2023年第二次临时股东大会、2023 年第二次 A 股类别股东 大会及 2023 年第二次 H 股类别股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2023 年 9 月 20 日 （二） 股东大会召开的地点：中国天津市河东区卫国道 126 号天津东凯悦酒店 二层悦宾厅 1 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 30 | | --- | --- | | 普通股股东人数 | 30 | | 其中：A 股股东人数 | 28 | | H 股股东人数 | 2 | | 2、出席会议的股东所持有的表决权数量 | 69,141,212 | | 普通股股东所持有表决权数量 | 69,141,212 | | 其中：A 股股东所持有表决权数量 ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: （8610）58091000 传真: （8610）58091100 北京市竞天公诚律师事务所 关于康希诺生物股份公司 2023 年第二次临时股东大会的 法律意见书 致：康希诺生物股份公司 本所律师根据《股东大会规则》第五条的要求，按照律师行业公认的业务标 准、道德规范和勤勉尽责精神，对本次股东大会召集和召开的有关事实及公司提 供的文件进行了核查和验证，现出具法律意见如下： 一、 本次股东大会的召集、召开程序 （一） 本次股东大会的召集程序 经本所律师查验，本次股东大会由公司董事会根据 2023 年 8 月 30 日召开的 公司第二届董事会第十四次会议决议召集。公司董事会于 2023 年 8 月 31 日以公 告方式向全体股东发出《康希诺生物股份公司关于召开 2023 年第二次临时股东 大会、2023 年第二次 A 股类别股东大会及 2023 年第二次 H 股类别股东大会的 通知》（以下简称"会议通知"）。该会议通知中载明了召开本次股东大会的时间、 地点、审议事项、股东大会投票注意事项和出席会议对象等内容。 （二） ...

Financial Performance - Revenue for the first half of 2023 was RMB 21,086 thousand, a decrease of 96.7% compared to RMB 629,790 thousand in the same period of 2022[7]. - Operating loss increased to RMB 1,342,432 thousand, compared to a loss of RMB 164,800 thousand in the first half of 2022, representing a 714.6% increase[7]. - Total comprehensive loss for the period was RMB 1,282,024 thousand, a significant decline from a profit of RMB 16,043 thousand in the same period last year, marking an 8,091.2% change[7]. - Basic and diluted loss per share was RMB (3.4098), compared to earnings of RMB 0.0495 per share in the first half of 2022, reflecting a 6,988.5% decrease[7]. - The company reported a net loss of RMB 841,429,000, compared to a profit of RMB 12,238,000 for the same period in 2022[109]. - The gross loss for the period was RMB (776,487) thousand, compared to a gross profit of RMB 316,173 thousand in the prior year[106]. - The company reported a loss before tax of RMB (1,283,335,000), compared to a loss of RMB (41,555,000) for the same period in 2022, indicating a significant increase in losses[143]. - The basic loss per share for the six months ended June 30, 2023, was RMB (3.41), compared to a profit of RMB 0.05 per share for the same period in 2022, reflecting a substantial decline in profitability[146]. - The company did not declare or pay any dividends for the six months ended June 30, 2023, following a total dividend payout of RMB 197,560,000 for the previous year[148]. Assets and Liabilities - Total assets decreased by 13.7% to RMB 9,897,272 thousand as of June 30, 2023, down from RMB 11,468,960 thousand at the end of 2022[8]. - Total equity decreased by 17.6% to RMB 5,969,259 thousand, compared to RMB 7,245,602 thousand at the end of 2022[8]. - The company's total liabilities decreased by 14.3% from approximately RMB 791.9 million as of December 31, 2022, to approximately RMB 678.8 million as of June 30, 2023, primarily due to a decrease in wages and benefits payable of approximately RMB 77.9 million[62]. - The company's total liabilities decreased from RMB 63,095,000 as of January 1, 2022, to RMB 56,936,000 as of June 30, 2023[160]. - The company’s total liabilities increased, with borrowings repaid amounting to RMB 1,229,022,000 during the period[110]. - The company’s total equity attributable to owners decreased to RMB 5,912,489,000 as of June 30, 2023, from RMB 6,748,090,000 at the beginning of the year[109]. Research and Development - The company has a diverse vaccine product line, including innovative vaccines targeting unmet medical needs globally[12]. - Ongoing research includes mRNA COVID-19 vaccines and tuberculosis booster vaccines, indicating a focus on advanced vaccine development[12]. - The company aims to expand its market presence with a broad portfolio of vaccines addressing over ten disease areas[12]. - The company has initiated Phase III clinical trials for the potential best-in-class PCV13i vaccine, with completion of site work in 2022 and plans to start new drug application procedures in the second half of 2023[20]. - The innovative PBPV vaccine, which targets over 90 serotypes of pneumonia, has entered Phase Ib clinical trials as of March 2023, with all subjects enrolled[21]. - The infant DTcP vaccine has officially started Phase III clinical trials in August 2023, with the first subject enrolled, aiming for new drug application procedures in 2025[22]. - The company is developing a Tdcp vaccine for adolescents and adults, which has received clinical trial approval from the National Medical Products Administration in June 2023, with Phase I trials expected to start in the second half of 2023[24]. - The company has obtained exclusive global licensing from McMaster University for the Ad5Ag85A tuberculosis vaccine, which has shown good safety and tolerance in Phase Ia trials, with plans to initiate new drug clinical trial applications in Indonesia in 2024[25]. - The recombinant shingles vaccine developed by the company has received a no-objection letter for clinical trials from Health Canada in July 2023, with both intramuscular injection and aerosol inhalation methods approved for trials[26]. - The company’s tetanus vaccine, developed using animal-free culture media, has received clinical trial approval for individuals aged 18 and above, with Phase I trials expected to start in 2023[27]. - The mRNA COVID-19 vaccine is still in clinical trials, with future development plans contingent on the tracking of variant strains and national immunization strategies[28]. Market and Sales - The revenue from the company's meningococcal vaccine products reached approximately RMB 222.6 million, up from RMB 10.6 million in the same period of 2022, driven by ongoing marketing and commercialization efforts[36]. - The company plans to continue the commercialization of its vaccines and strengthen its marketing efforts to enhance public awareness of vaccination[35]. - The company has established a comprehensive commercial operation center and aims to expand its marketing network while controlling sales expenses[35]. - The company will continue to explore global collaborations and acquisitions related to vaccines and bioproducts to enhance its international market competitiveness[35]. Cash Flow and Investments - The total cash used in operating activities was RMB 753,907,000, an improvement from RMB 1,215,901,000 in the previous year[110]. - The company invested RMB 2,815,000,000 in equity and fund investments during the period, a decrease from RMB 6,681,912,000 in the previous year[110]. - The company plans to invest approximately RMB 2,244.7 million in the CanSino Innovative Vaccine Industrial Park project to enhance manufacturing capabilities, with RMB 376.2 million already invested[68]. - The company has established foreign exchange risk hedging agreements with several commercial banks to mitigate foreign exchange risks[71]. - The company has repurchased 683,748 A-shares at a total cost of approximately RMB 150.2 million, which includes transaction costs of RMB 152,000[99]. Shareholder Information - As of June 30, 2023, Dr. Yu holds 34,598,400 H shares (13.98%) and 42,579,625 A shares (17.21%), representing approximately 26.08% and 37.10% of the respective classes of shares[83]. - The Capital Group Companies, Inc. holds 16,747,482 H shares (6.77%), accounting for approximately 12.62% of the total equity[88]. - JPMorgan Chase & Co. holds 7,335,430 H shares (2.96%) and has additional positions in 4,838,049 shares (1.96%) and 1,730,219 shares (0.70)[88]. - Qiming Corporate holds 7,516,538 H shares (3.04%), representing approximately 5.67% of the relevant class of shares[89]. Compliance and Governance - The audit committee reviewed the unaudited interim results for the six months ended June 30, 2023, and found them compliant with applicable accounting standards[80]. - The company’s independent auditor, Deloitte, conducted a review of the interim financial information in accordance with the relevant standards[81]. - The company has no other disclosures regarding the interests or short positions of directors or senior management in the company’s shares as of June 30, 2023[86]. - The company’s major shareholders, excluding directors and senior management, have disclosed their interests in the company’s shares as required by the Securities and Futures Ordinance[87]. - The company’s board consists of three independent non-executive directors overseeing financial reporting and risk management systems[80].